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43 Objectives: The objective of the present work to encapsulate the resveratrol (RES) inside the 
44 chitosan-based microsponges, employing the systematic optimization by 33 Box-Behnken 
45 design for the colonic targeting.
46 Significance: Enhanced therapeutic efficacy of RES-loaded microsponges and matrix tablets, 
47 vis-a-vis pureRES for ulcerative colitis.
48 Methods: RES-loaded microsponges were prepared employing the systematic optimization 
49 by 33 Box-Behnken design for the colonic targeting. The best-optimizedRES-loaded 
50 microsponge was compressed in the form of a tablet, employing pectin as a matrix-forming 
51 material. The encapsulation of RES inside microsponge was confirmed by XRD, DSC and 
52 FT-IR. Further, both RES-load d microsponges and matrix tablets were evaluated for in vitro 
53 release kinetics and further evaluated for in vivo ulcerative colitis animal model.
54 Results:Optimization experiments was obtained as the high value of r2 (particle size = 
55 0.9999; %EE= 0.9652; %CDR = 0.9469) inferred excellent goodness of fit. SEM revealed 
56 nearly spherical and porous nature of RES-loaded microsponges. The in vitro release kinetic 
57 showed zero-order release for RES-loaded microsponges and Korsmeyer-Peppas model for 
58 matrix tablets.The pharmacodynamic studies, in ulcerative colitis rat model, indicated better 
59 therapeutic efficacy of drug-loaded microsponges and matrix tablets, vis-a-vis pure RES. 
60 Thus,the present study advocates the potential of RES based microsponges delivered by 
61 pectin based matrix tablet, in the treatment of various colonic disorders.  
62 Conclusion: The present study proved that RES-loaded microsponges and matrix 
63 tablets based on chitosan and pectin, can be the ideal delivery system for colonic 
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73 Keywords:Chitosan;Box-behnkendesign;quasi emulsion solvent diffusion method; pectin; 
74 ulcerative colitis; release kinetics.
75 Introduction
76 Resveratrol (RES) (3,5,4’-trihydroxystilbene), is a non-flavonoid polyphenolic phytoalexin 
77 molecule, synthesized by various plant species like grapes,  berries, and peanuts, in response 
78 to stress and microbial infections[1, 2]. RES acts as a strong antioxidant by inhibiting reactive 
79 oxygen species (ROS) primarily by activating protein kinase and suppresses cyclooxygenase 
80 (COX-2), and lipid peroxidation. It has demonstrated its therapeutic roles as anti-
81 inflammatory, analgesic, cardio-protective, neuroprotective, chemo-preventive, and anti-
82 aging agents [3]. There are many reports available for its decent therapeutic efficacy for 
83 lower gastrointestinal (GI) diseases like ulcerative colitis, peptic ulcer, Crohn’s diseases and 
84 colon cancer [4, 5]. Despite of high oral absorption (~ 75%), the oral bioavailability of RES 
85 is less than 1%, due to its extensive intestine and liver metabolism [6, 7]. Moreover, rapid 
86 absorption in the upper GI tract and pre-systemic metabolism subsequently results in the 
87 lower amount of drug reaching to the colon [8, 9]. Thus, there is a necessity to develop an 
88 efficient drug delivery system for RES, which would be able to target the drug directly to the 
89 colon and prevent its release in the upper GI tract.
90 Novel drug delivery carrier systems viz. nanoparticles, nano-spheres, micro-particles, 
91 microspheres, beads and micro/nano-sponges based on various polymers, have been 
92 consumedfor colon-specific drug delivery[10-13]. These systems are, controlled by GI transit 
93 time, GI pressure differences, GI pH differences, and colonic bacterial enzymes [14]. In the 
94 recent past, polysaccharides that are particularly metabolised by the colonic flora have 
95 increased acceptance as a colon-specific drug delivery systems. Pectin, a linear 
96 polysaccharide is extensively used as a colon-specific matrix carrier due to some attractive 
97 features, viz. hydrophobicity, and ability to form gel, biodegradability, and persistence to 
98 intestinal enzymes. The other polymer in the polysaccharide class is chitosan, which is pH-
99 sensitive and is used as a colon-specific carrier owing to its ability to restrict the drug release 
100 in the gastric pH, and significantly release the drug at higher pH [15]. Based on the above 
101 considerations, the advantages of both chitosan and pectin for colon-specific delivery of RES 
102 were combined into a unit dosage form, wherein chitosan was employed in the form of 
103 microsponges, and pectin as a matrix-forming material. Microsponges have the competency 
104 to encapsulate and adsorb a high degree of active ingredients onto its surface owing to 
105 numerous interconnected pores. Apart from high drug entrapment, and site-specificity, 
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106 microsponges have a specific property of retaining on the surface of the colon, and thereby, 
107 increase the absorption of the drug in the colon [16, 17]. Further, it can prevent the drug from 
108 early absorption, as the drug is enclosed inside the micro-sponge, and also the frequency of 
109 dosing may be decreased via controlled delivery of drug over a longer period of time, and 
110 hence the patient compliance [18].
111 Polymeric erosion based matrix systems comprising of hydrophilic polymer is highly popular 
112 in tablet manufacturing for controlled release application. Such matrix system, retard the drug 
113 release, owing to the formation of the gelatinous surface layer due to swelling in the aqueous 
114 medium, which controls the diffusion of water when placed in an aqueous medium[19, 20]. 
115 The present work was designed to systematically optimize the RES-loaded chitosan 
116 microsponges employing Box-behnken design with respect to particle size, entrapment 
117 efficiency, and percent cumulative drug release. The best-optimized RES loaded microsponge 
118 formulation was developed into the erosion based matrix tablet employing pectin. Finally, all 
119 the RES formulations were evaluated employing an acetic-acid induced ulcerative colitis 
120 model in rats. 
121 Experiment
122 Materials
123 RES was received ex gratis from Tirupati Medicare Ltd., PaontaSahib, Sirmaur, Himachal 
124 Pradesh, India. Acetone, sodium chloride, polyvinyl alcohol (PVA), sodium dihydrogen 
125 phosphate, potassium dihydrogen phosphate, sodium hydroxide (NaOH), and pectin, were 
126 procured from Nice Chemical Pvt. Ltd., Cochin, India. Ethanol, and HCl were purchased 
127 from Merck Specialties Pvt. Ltd., Mumbai, India, while Span 80, was purchased from 
128 Qualikems Laboratory Reagents, New Delhi, India. Chitosan was purchased from Hi-Media 
129 Laboratory Pvt. Ltd., Mumbai, India, while, PVP K30, and microcrystalline cellulose (MCC), 
130 were obtained from Loba Chemical Pvt. Ltd., Mumbai, India.
131 Methods
132 Fabrication and evaluation of microsponges
133 Microsponge preparation was done by quassi-emulsion technique as previously reported by 
134 authors [21]. Methanol was employed as a solvent to dissolved RES. 0.1 mL of internal 
135 aqueous phase was added into the organic phase to form w/o primary emulsion. Herein, the 
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136 internal phase comprised of 1% (w/v) aqueous solution of NaCl (as porogen) and Span 80. 
137 The organic phase was prepared in the DCM. Separately, chitosan was dissolved in minimum 
138 amount of 1% w/v aqueous solution of the glacial acetic acid solution, and RES was 
139 dissolved in methanol. Both the solution was then added to the required volume of DCM to 
140 form the organic phase. Finally, primary w/o emulsion was added into 5% w/v aqueous PVA 
141 (external phase), to form w/o/w double emulsion. The prepared emulsion was then, 
142 continuously stirred for 2h on a mechanical stirrer. Microsponges so prepared were filtered, 
143 dried at 60˚C, and stored in the desiccator until further use[22].
144 Systematic optimization of microsponges as per the experimental design
145 RES-loaded microsponges were optimized employing three factor three-level, Box–Behnken 
146 design (BBD). The dependent variables were the amount of RES (X1), polymer (X2), and 
147 solvent (X3), used at three different levels of each variable, viz. low (-1), intermediate (0), 
148 and high (+1). Various microsponge formulations (Table 1) prepared as per the design were 
149 investigated for the response variables like particle size, percent cumulative drug release (% 
150 CDR), and percent entrapment efficiency (%EE) as the response variables.
151 Characterization of microsponges
152 Particle size determination
153 The mean particle size of microsponge was analysed by Malvern Master Sizer (Scinrocco, 
154 2000), installed at the University Institute of Pharmaceutical Sciences (UIPS), Chandigarh, 
155 India. All the samples were diluted 50 times before analysis. The samples were then placed 
156 into cuvettes and the intensity of fluctuation of the laser beam was recorded and interrelated 
157 with the particle size of the dispersed phase[23].
158 Entrapment efficiency (%EE), percentage yield (%Y) and percentage drug loading(%DL)
159 For %EE, microsponge equivalent to 10 mg of the drug were crushed and extracted 
160 employing methanol by ultra-sonication. To separate the insoluble residue, centrifugation was 
161 then carried out at 2000 rpm for 10 min. The supernatant was analysed by the U.V 
162 spectrophotometer (Systronics-Model-2202) atλmax302 nm after appropriate dilution [24]. To 
163 determine the concentration of RES, the value of absorptivity used was 1437. The amount 
164 of% EE, % Y and %DL was calculated employing the following Equations (1),(2) and (3) 
165 respectively.
Page 6 of 31
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
6
166 (1)%𝐸 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑠𝑝𝑜𝑛𝑔𝑒
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 × 100
167 (2)%𝑌 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑠𝑝𝑜𝑛𝑔𝑒
𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 + 𝐼𝑛𝑖𝑡𝑖𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓𝑝𝑜𝑙𝑦𝑚𝑒𝑟 × 100
168 (3)%𝐷𝐿 =
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑠𝑝𝑜𝑛𝑔𝑒
𝑀𝑎𝑠𝑠 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝𝑜𝑛𝑔𝑒 × 100
169 In vitro drug release
170 In vitro dissolution study of RES for a period of 12 h, from all the prepared microsponge 
171 formulations, was carried out employing the USP–Type-II dissolution 
172 apparatus(ElectrolabETC 11LX) [25]. Microsponges equivalent to 10 mg of the RES, was 
173 placed in the jar, and the study was performed at different pH, i.e. pH 1.2 (200mL), for 2 h, 
174 pH 6.8 for 2-6 h and pH 7.4 (700 mL) for subsequent hours i.e., 6-12 h to simulate the same 
175 conditions of GIT. The stirring was maintained at 100 rpm at 37±5˚Ctemperature. Samples (5 
176 mL) were withdrawn periodically at regular time intervals (0, 0.5 1.5, 2, 3, 4, 6, 8,10, 12h) 
177 while an equal volume of fresh medium was added to maintain the sink conditions. The 
178 samples were diluted with methanol and analysed spectrophotometrically at λmax302 nm to 
179 calculate the percent cumulative drug release (%CDR) values [26].
180 Optimisation data analysis and validation
181 The optimization and validation of data obtained for various response variables viz., particle 
182 size, %EE, and %CDR were performed employing mathematical modelling. The second-
183 order quadratic polynomial model was selected using multiple linear regression analysis 
184 (MLRA) to study the probability of a significant interaction(s) among the response 
185 variables[27, 28]. The response surface analysis was studied employing three dimensional 
186 (3D) response surface plots, and two-dimensional (2D) contour plots, constructed using 
187 Design Expert® ver.10.0.1 (Stat-Ease Inc., Minnepolis, MN). The numerical optimization 
188 using desirability function by ‘trading off’ of the response variables was employed to select 
189 the optimum microsponge formulation (RES:340 mg; polymer; 455 mg). A total of ten 
190 check-point microsponge formulations were selected and evaluated. The observed and 
191 predicted values for the studied responses, i.e. particle size, %CDRand %EE, were critically 
192 compared. Percent bias (percent error) was determined with respect to the observed responses 
193 and the residual plots were also generated.
194 Characterization of the optimized microsponge formulation
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195 Scanning electron microscopy
196 To observe the surface of microsponge, dried samples were mounted on a metal stub using 
197 double-sided adhesive tape and sputter-coated with gold for 1 min. under vacuum and then 
198 observed under a scanning electron microscope (SEM) at 10 kV (QUANTA 250, FEI 
199 Makers, Singapore), installed at IIT, Mandi, H.P, India[27].
200 Differential scanning calorimetric (DSC) analysis
201 DSC (STA 449 F1 Jupiter) thermal analysis was carried out, on the optimized RES-loaded 
202 microsponge formulation, pure RES, and chitosan. Approximately 5mg sample was weighed, 
203 and sealed into aluminium pans. All the samples were heated at the rate of 10°C/min in a 
204 temperature range of 25-300°C, in nitrogen atmosphere [29].
205 Thermal gravimetric analysis (TGA)
206 TGA (STA449F1 Netzsch) thermal analysis was carried out, on the optimized RES-loaded 
207 microsponge formulation, pure RES, and chitosan. Approximately 5mg sample was weighed, 
208 and sealed into aluminum pans. The experiment was conducted in temperature range of 25-
209 300°C at a heating rate of 10°C/min in a temperature range of 25-300°C, in a nitrogen 
210 atmosphere (20 ml/min) [29, 38].
211 X-ray powder diffraction (XRD) study
212 XRD was recorded to characterize the crystal and physical state of microsponge, pure RES 
213 and chitosan. The instrument (SmartLab 9kW rotating anode x-ray diffractometer) was 
214 operated at a voltage of 45mV and current 20A, and the diffraction patterns over a range of 5-
215 10°C/min in terms of 2Ø [29]. 
216 Formulation and evaluation of colon-targeted matrix tablet
217 Colon targeted matrix tablets of optimized RES-loaded microsponges were prepared by direct 
218 compression method. Pectin (150 mg, matrix diluent), optimized microsponge formulation 
219 (150 mg),polyvinyl pyrollidine (PVPk30) (binder, 150 mg), and microcrystalline cellulose 
220 (MCC, 50 mg) were accurately weighed and mixed uniformly to form a homogenous 
221 powder-mixture. The final mixture was then passed through sieve no. 22, and was directly 
222 compressed into tablets, employing Rotatory tablet punching machine (Cadmech. Pvt. 
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223 Ltd.)[30].Tablets were evaluated for various pharmacopoeial (weight variation, friability and 
224 in vitro dissolution) and non- pharmacopoeial (hardness) aspects.
225 The in vitro dissolution of the matrix tablets was done as describes in section 2.4.3. The 
226 weight variation of the matrix tablets was determined as per Indian Pharmacopoeia [31]. 
227 Briefly, twenty tablets were weighed and the average weight was calculated. The percentage 
228 of weight variation was also determined by using the following formula as shown in the 
229 Equation. (4)
230 (4)%  Weight Variation =
Individual weight ― Average Weight
Average Weight x100
231 The friability of prepared matrix tablets was determined with Roche type friabilator. 10 
232 tablets were weighed and tested at a speed of 25 rpm for 4 min. After the process was 
233 stopped, tables were removed out of the friabilator then after, dust was wiped-off, and tablets 
234 were weighed again. The difference between the weight before, and after, the process, was 
235 determined. The percentage friability (%) was calculated using the following Equation (5)
236 (5)%Friability =
Tablet weight  before ― Tablet weight after 
Tablet weight after x100
237 The hardness of the prepared matrix tablets was determined to employ Monsento hardness 
238 tester. The hardness was measured in terms of force (Kg/cm2), required to break the tablet. 
239 The tablet was placed between two anvils, the force was applied, until the tablet breaks and 
240 this force was recorded. The hardness test was performed on twenty tablets, and the average 
241 hardness was recorded [31]. 
242 In vitro drug release kinetics
243 Release data from the best-optimized microsponge formulation and its matrix tablet were 
244 fitted to various mathematical models to study the drug release mechanisms. The various 
245 models employed were zero-order (% cumulative drug release vs. time) Equation(6), first-
246 order (log % drug release vs. time) Equation (7), Higuchi model (% cumulative drug release 
247 vs. square root of time) Equation(8), and Peppas model (log % drug release vs. log time) 
248 Equation(9). The kinetic model was selected based on best fit with the highest value of the 
249 regression coefficient (r2) [7, 21]. 
250 Qt= k0t                             (6)
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251 lnQt= lnQα+k1t            (7)
252 Qt = k√t(8)
253 Qt = kkt
(9)
254
255 Here Qt is the amount of drug released at time t, Qα is the initial amount of drug, whereas, k0, 
256 k1, k and kk are the corresponding release rate constants for zero-order, first-order, Higuchi and 
257 Korsmeyer-Peppas model respectively.
258 In vivo pharmacodynamic study
259 The animal study was carried out in prior approval of the Animal Ethical Committee, of 
260 Shoolini University Animal Ethics Committee, duly approved for the purpose of control and 
261 supervision of experiments on animals by the Government of India, (IAEC No/SU- 
262 PHARM/7/10).
263 Acetic acid-induced experimental ulcerative colitis in the colon
264 Fifteen wistar albino rats (body weight = 160–200 g), were taken, and caged individually 
265 with food and water ad libitum). The rats were distributed randomly into five groups with 
266 each group comprising of three animals. Except for the negative control group, colitis was 
267 induced in all the groups by intrarectal administration of 1 mL of (4%) (v/v) acetic acid, 
268 which resembles with the inflammatory bowel disease (IBD). The catheter was introduced 
269 into the anus up to a length of 6 cm, and then acetic acid was administered [32]. The  full IBD 
270 model was developed by keeping animals untreated for about three days [30]. After three 
271 days, each group received the treatment orally in 0.5% carboxymethyl cellulose (w/v) 
272 solution. Group 1 served as a negative control, group 2 served as colitis group without any 
273 treatment, group 3 received pure RES (25mg/kg), group 4 received RES -loaded 
274 microsponges (equivalent to 25mg/kg), and group 5 received RES-loaded microsponge 
275 matrix tablets (equivalent to 25mg/kg) [33]. 
276 Pharmacological Assessments
277 After seven days of treatment, the animals were sacrificed and colon was removed, and based 
278 on inflammatory scales, and ulcer projections were visualized. The inflammatory scales were 
279 categorised as; 0 = normal coloured colon, 0.5 = red coloration, 1 = spot ulcer, 1.5 = 
280 haemorrhagic streaks, and 2 = haemorrhagic ulcer.
281 Histopathology assessment
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282 Histopathological analysis was performed by preserving the part of the colon in a 10% 
283 formalin solution. These colonic sections were stained with hematoxylin and eosin (H&E) 
284 and examined using a light microscope with a fitted Nikon camera for the presence of any 
285 necrosis, ulceration, haemorrhage, and inflammatory cell infiltration [34].
286 Results and discussion
287 Formulation and optimization of microsponges
288 In the present research, quassi emulsion technique was used to fabricate the various RES-
289 loaded microsponge formulations. Chitosan was employed as a polymer for the preparation 
290 of microsponge due to its ability to release the drug, particularly at the colonic site. The 
291 prompt mixing of w/o primary emulsion and water at the interface resulted in the 
292 precipitation of RES-loaded structures of chitosan. For the optimization RES-loaded 
293 microsponges, a three-factor, three-level, the Box-Behnken design was employed. Table 1 
294 summarises an account of the 17 experimental runs studied, along with the coded values and 
295 actual values for the studied factors. Various microsponge formulations fabricated as per the 
296 design were investigated for %EE, %CDR and particle size as the response variables.
297 [Space for Table 1]
298 Response surface mapping and data analysis
299 The data analysis of the response variables employing second-order quadratic polynomial 
300 models [27, 28], suggested that the quadratic model was highly significant (p<0.05) along 
301 with the model terms (p<0.0001).The special polynomial mathematical model encompassing 
302 ten coefficients (β0- β33) represent quadratic and interaction terms, as shown in 
303 Equation(10). 
304 Y=β0 + β1X1 + β2X2 + β3X3 + β12X1X2 + β13X1X3 + β23X2X3 + β11X12 + β22X22 + 
305 β33X32    (10)
306 A very high degree of predictive ability of the optimization experiments was obtained as the 
307 value of overall bias was 0.1109 ± 0.2253%. Further the high value of r2 (particle size = 
308 0.9999; %EE= 0.9652; %CDR = 0.9469) inferred excellent goodness of fit. The residual plots 
309 were found to be uniform, comparatively narrow and random scatter around the zero-axis 
310 [27, 35].
311 [Space for Table 2]
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312 Figure 1, depicts 2D-contour plots and corresponding 3D-response surface plots for % EE 
313 (A), %CDR (B), and particle size (C). In the current studies, polymer and drug concentration 
314 had a greater effect on all the studied response variables, out of all the studied input variables. 
315 A curvilinear dip in the values of % EE followed by an increasing trend was observed with an 
316 increase in the drug concentration, and a decrease in polymer concentration as shown in 
317 Figure 1A. In case of %CDR, a twisted shape curve was observed with an increase in both 
318 drug as well as polymer concentration as given in Figure 1B. An increase in polymer 
319 concentration negatively influenced the %CDR, while, an increase in drug concentration 
320 enhanced the former. This can be attributed to the fact that the drug release from the polymer 
321 matrix occurs after c mplete swelling of the polymer, and as the quantity of polymer in the 
322 formulation increases, so the time required to swell also increases, and hence, slower the drug 
323 release. In the case of particle size shown in Figure 1C, a linear relationship was obtained for 
324 polymer and drug concentration. With the increase in polymer or drug concentration, particle 
325 size was increased, however, the effect was more pronounced in case of polymer 
326 concentration. The increase in the polymer concentration results in an increase in the 
327 viscosity of the internal phase, which subsequently gives rise to the generation of more 
328 viscous forces resisting droplet breakdown, and thus bigger sized particles. The search for 
329 optimum microsponge formulation was carried out using numerical optimisation and 
330 desirability function to get the required goals for the response variables. Table 3 presents the 
331 constraint set for numerical optimisation. In model validation, a total of ten check-point 
332 formulations were selected from the RSM. Hence, based on these parameters the best 
333 formulation was selected and further used for characterization.
334 [Space for Figure 1]
335 [Space for Table 3]
336 Percentage yield (%Y) and Drug loading (DL)
337 The %Y of all the prepared microsponges ranged between 69.45±0.52-86.68±0.67%, while 
338 %DL values were in the range of 40.1±0.34-71.45±0.76%. With an increase in the drug 
339 concentration, %Y and %DL were found to be increased. This might be due to the high drug 
340 and polymer concentration, which led to increase in viscosity of the dispersed phase, and  
341 reduced the diffusion rate of DCM from viscous solutions into the aqueous phase, thus 
342 improving the yield and loading [36]. 
343
344 Characterization of optimized formulation
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345 Surface morphology
346 The SEM image revealed formulation to be of nearly spherical shape having sufficient 
347 surface porosity as shown in Figure 2a. The presence of numerous interlinked pores all over 
348 the particle was also present imitating the spongy structure.
349 X-ray powder diffraction (XRD) study
350 The XRD pattern of pure RES, polymer, and optimized microsponge formulation were 
351 recorded, and the overlay-XRD spectrum is shown in Figure 2b.RES showed numerous sharp 
352 and intense diffraction peaks at 13.3, 16.4, 19.2, 22.4, 25.3, 28.3 and 45.3°, which indicates 
353 crystalline nature at the respective 2Ø positions. The polymer chitosan did not show any 
354 peaks, suggesting its amorphous nature as depicted in literature. The microsponge 
355 formulation also did not reveal any peaks of polymer and drug, indicating the entrapment of 
356 drug inside the microsponges [29].
357 FT-IR spectra
358 The overlay FTIR spectra of RES, Chitosan and microsponge formulation is depicted in 
359 Figure 2c.RES exhibited three strong absorption bands at 1611 cm-1, 1588 cm-1, and 1387.90 
360 cm-1, analogous to C-C aromatic double bond stretching, C-C olefinic stretching, and C-C 
361 stretching, respectively. The peaks from 3167 to 3201 cm-1depicts the O-H stretching and the 
362 peak at 1561cm-1correspond to aromatic C=C bending. The peak at 1447 cm-1 corresponds to 
363 C-C ring stretching [37]. The characteristic chitosan peaks belonging to its saccharide 
364 structure at 1055 and 898 cm−1 and at 1655 cm−1 (amide I) were close to the literature value. 
365 FTIR spectra of RES-loaded microsponges displayed all peaks analogous to pure RES and 
366 chitosan, however, with a decreased intensity of peaks. Further, the RES-loaded 
367 microsponges did not show any major peaks corresponding to the bioactive incorporated. 
368 This indicates the encapsulation of the RES within the microsponge formulation.
369 Differential scanning calorimetric (DSC) analysis
370 DSC thermograms of the drug, chitosan, and RES-loaded microsponge formulation are 
371 shown in Figure 2d. The drug RES demonstrated an endothermic peak around 260°C, which 
372 is very close to the melting point of the drug, i.e., 261°C to 263°C. Chitosan revealed an 
373 endothermic peak, at around 220°C, which is close to its reported value. In the case of 
374 microsponge formulation, there was no peak of RES and chitosan, which indicates the 
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375 complete entrapment of drug inside the microsponge formulation and the amorphous state of 
376 microsponge formulation [29, 38]. 
377 Thermal gravimetric analysis (TGA)
378 TGA thermograms of the RES-loaded microsponge formulation, pure RES, and chitosan, are 
379 shown in Figure 2e.  TGA thermograms of chitosan indicated the % weight loss of 
380 approximately 90% of the polymer ranges between 260 -290°C as shown in figure 2e (A). 
381 whereas the % weight loss of drug found to be approximately 80% ranges between 220-
382 270°C has shown in figure 2e (B). Drug-loaded Optimized microsponge formulation showed 
383 TGA thermogram at a temperature range between 110°C - 190°C signifying that the drug was 
384 either completely or partially changed into amorphous form [38].
385                                                   [Space for Figure2] 
386 Evaluation of RES-loaded microsponge matrix tablets
387 All the evaluation parameters of matrix tables are shown in Table 4 and suggest its 
388 satisfactory characteristics. The formulations exhibited a hardness of 4.13±0.13kg/cm2 and 
389 friability below 0.69±0.23% which showed satisfactory mechanical strength of the tablets. 
390 The average weight of the twenty tablets was found to be 499.65 ±1.35  which is well within 
391 the IP limit of weight variation i.e.(±5%).
392 [Space for Table4]
393 In vitro release of RES-loaded microsponges matrix tablets
394 The in vitro release pattern of RES, from plain microsponges, and microsponge-matrix tablet 
395 is shown in the Figure 3. The rate of drug release in 12 h was gradually increased, with an 
396 increase in time, and then became constant or attained equilibrium, in optimized microsponge 
397 formulation. Drug release mechanisms from microsponge could be linked to its porous 
398 surface. The latter permits easy penetration of the release media, and its approachability to 
399 the entrapped drug. It was witnessed that the microsponge system was able to control the 
400 drug release in gastric pH i.e., only 10% of the drug was released during an  initial 2h. 
401 However, the drug release from matrix tablets at all the pH conditions was on the lower side 
402 vis-à-vis microsponge formulation. This could be due to the slow swelling property of the 
403 pectin, followed by gradual erosion, and release of the drug from the matrix tablets [17, 21]. 
404 It is well reported that the drug release from a swellable hydrophilic polymer like pectin can 
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405 be controlled and relating the liquid penetration within the polymer matrix, the swelling of 
406 the hydrated polymer, drug diffusion throughout the swollen matrix and, erosion. PVP due to 
407 its water-soluble characteristic could help in the solubilization in the aqueous phase and helps 
408 in the permeation of dissolution media through the matrix causing its erosion [21].
409 [Space for Figure3]
410 Kinetic release analysis of  drug 
411 The fitting of drug release data by suitable mathematical models is a powerful tool, which not 
412 only enables the better interpretation, and comprehension of the mechanisms involved in the 
413 drug release process but also helps in controlling the release features according to specific 
414 therapeutic needs. Different mathematical models as shown in Table 5 were applied to in 
415 vitro drug dissolution profiles and their respective coefficients were estimated.
416 According to r2 values, as shown in Table 5, it can be noted that the microsponge fitted better 
417 with the zero-order kinetic model, while the microsponge tablets fitted best with the Peppas 
418 model. In the Korsmeyer-Peppas model, the value of n specifies the release mechanism of the 
419 drug as defined. For the case of spherical matrix tablets, 0.43 ≤n corresponds to a Fickian 
420 diffusion mechanism, 0.43 < n < 0.85 to non-Fickian transport, and n > 0.85 to super case II 
421 transport [35]. Here, the value of n was determined to be more than 0.85, thus mimicking the 
422 super case II transport kinetics.
423 [Space for Table5]
424 In vivo pharmacodynamic study
425 After the completion of in vivo pharmacodynamic study, rats were sacrificed, and colon was 
426 examined visually, on the basis of inflammatory scales as shown in Table 6 [17,40]. It is 
427 vivid from the results that there were less colonic lesions seen in the case of treated groups 
428 vis-à-vis colitis group, indicating positive therapeutic outcomes of RES, RES-loaded 
429 microsponge, and microsponge-matrix tablets. 
430 [Space for Table 6]
431
432 Histopathological studies
433 All the histological pictures of various treated and untreated groups are depicted in Figure 4. 
434 While negative control group as shown in Figure 4A, revealed healthy looking mucosal or 
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435 sub-mucosal lining, and intact mucosal crypt, acetic acid-induced colitis group (Figure 4B) 
436 showed severe surface, and mucosal haemorrhage (white arrows), marked necrotic 
437 alterations, and leftovers of colonic crypts (black arrows). Besides, the sub-mucosal layer in 
438 the acetic acid-induced colitis group revealed polymorphic inflammatory cell infiltration 
439 (stars). Thus, it can be concluded that the colitis group revealed severe mucosal ulceration, 
440 inflammatory cell infiltration, submucosal edema, and goblet hyperplasia [40] Figure 
441 4Cpertaining to the pure RES treated group showed colonic mucosa with no haemorrhage 
442 streak, mild preservation of crypts with slight dilations, and almost intact mucosal lining cells 
443 (arrows). Microsponge formulation treated group, i.e. (Figure 4D), and microsponge-matrix 
444 tablet treated group, (Figure 4E) revealed intact mucosal crypts, healthy mucosal and 
445 submucosal lines, suggesting both the formulations to preserve the normal colonic condition. 
446 However, RES-loaded microsponge treated group revealed much prominent results in 
447 comparison to the microsponge-matrix tablet treated group. Overall, all the RES treated 
448 groups exhibited the complete cur  of ulcerative colitis after the 7th day [33].
449 [Space for Figure 4]
450 Conclusion
451
452 The present study successfully ratified that the chitosan microsponge were able 
453 to entrap the RES. The systemic optimization employing BBD aided in studying 
454 the most influential variables to select the best-optimized formulation. The in 
455 vitro release kinetics data revealed the sustained release nature of the developed systems. 
456 Finally, in the in vivo ulcerative colitis model, better therapeutic outcomes from 
457 drug-loaded microsponge, and microsponge loaded matrix tablets were achieved 
458 vis-à-vis pure RES. Overall, the present studies corroborated that the developed 
459 microsponges matrix system based on chitosan and pectin can be the ideal 
460 delivery system for colonic delivery of RES.
461
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Figure 1. Two-dimensional contour plots and corresponding three-dimensional response surface 
plot depicting the effect of various input variables on; (A) Entrapment Efficiency, (B) 
%CDR(cumulative drug release), and (C) Particle Size.
Figure 2. a) SEM image of resveratrol-loaded microsponge formulation (Magnification 8000 x) 
b) XRD spectra of drug, polymer and microsponge formulation c) FTIR spectra for resveratrol, 
chitosan and resveratrol-loaded microsponge formulation d) Heating curves of differential 
scanning calorimetry (DSC) for polymer, drug and microsponge formulation e) Thermal 
gravimetric analysis (TGA) of polymer, drug and microsponge formulation.
Figure 3. Comparision of % CDR between optimized resveratrol-loaded microsponge 
formulation and resveratrol-loaded microsponge-matrix tablet. Each cross bar indicates average 
value±SD (n=3).
Figure 4. Histology of colonic section of (A) Normal control group, (B) Acetic acid-induced 
colitis group, (C) Resveratrol treated group, (D) Resveratrol-loaded microsponge treated group, 
(E) Resveratrol-loaded microsponge-matrix tablet treated group.
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Fig. 1. Two-dimensional contour plots and corresponding three-dimensional response surface 
plot depicting the effect of various input variables on; (A) Entrapment Efficiency, (B) 
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Fig. 2. a) SEM image of RES-loaded microsponge formulation (Magnification 8000 x)b)XRD 
spectra of drug, polymer and microsponge formulation c)FTIR spectra for A) RESB) Chitosan 
and C) RES-loaded microsponge formulation d)Heating curves of differential scanning 
calorimetry (DSC) for polymer, drug and microsponge formulation e)Thermal gravimetric 
analysis (TGA) of polymer, drug and microsponge formulation..



















Fig. 3. Comparision of % CDR between optimized RES-loaded microsponge formulation and 
RES-loaded microsponge-matrix tablet. Each cross bar indicates average value±SD (n=3).
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Fig. 4. Histology of colonic section of (A) Normal control group, (B) Acetic acid-induced colitis group, 
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tablet treated group.White arrow indicates severe surface, and mucosal haemorrhage, Black arrow 
indicates marked necrotic changes, and remnants of colonic crypts and Star indicates the sub-mucosal 
layer revealing polymorphic inflammatory cell infiltration
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Table 1. Experimental runs of BBD design matrix and their responses






%EE %CDR Particle size 
(µm)
1 -1 0 -1 82.8 68.47 464.172
2 1 1 0 8                                                          
6.8
68.88 663.563
3 0 0 0 85 88.18 609.211
4 0 0 0 85 88.18 609.211
5 1 0 -1 83 81.74 471.391
6 0 1 -1 76 56.96 378.227
7 -1 -1 0 94 80.30 446.452
8 -1 0 1 87 70.71 853.771
9 1 -1 0 89.6 81.8 436.582
10 0 0 0 85 88.18 609.211
11 0 1 1 79 72.48 923.211
12 0 0 0 85 88.18 609.211
13 -1 1 0 82 62.97 686.98
14 1 0 1 93 78.52 869.236
15 0 -1 -1 84.6 87.61 395.606
16 0 0 0 85 88.18 609.211
17 0 -1 1 92 84.64 600.834
Level used, actual (coded)Independent variables
Low (-1) Medium (1) High (+1)
Drug 250 375 500
Polymer 250 375 500
Solvent 2.5 5 7.2
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%EE %CDR Particle size 
(µm)
1 -1 0 -1 82.8 68.47 464.172
2 1 1 0 8                                                  
6.8
68.88 663.563
3 0 0 0 85 88.18 609.211
4 0 0 0 85 88.18 609.211
5 1 0 -1 83 81.74 471.391
6 0 1 -1 76 56.96 378.227
7 -1 -1 0 94 80.30 446.452
8 -1 0 1 87 70.71 853.771
9 1 -1 0 89.6 81.8 436.582
10 0 0 0 85 88.18 609.211
11 0 1 1 79 72.48 923.211
12 0 0 0 85 88.18 609.211
13 -1 1 0 82 62.97 686.98
14 1 0 1 93 78.52 869.236
15 0 -1 -1 84.6 87.61 395.606
16 0 0 0 85 88.18 609.211
17 0 -1 1 92 84.64 600.834
Level used, actual (coded)Independent variables
Low(-1) Medium(1) High(+1)
Drug 250 375 500
Polymer 250 375 500
Solvent 2.5 5 7.2
Table 2. Polynomial mathematical model data
Coefficient code Second-order Polynomial coefficients for response variables
Page 29 of 31
URL: http:/mc.manuscriptcentral.com/lddi  Email:hugh.smyth@austin.utexas.edu





























































For Peer Review Only
%EE %CDR Particle size
β0 85 88.18 609.211
β1 0.825 3.5275 -0.07537
β2 -4.55 -9.1325 96.58588
β3 3.075 1.4125 193.4795
β11 2.3 1.1025 -3.38675
β22 1.45 -1.2975 4.5615
β33 -1.1 4.6225 84.984
β12 3.325 -7.59375 20.90563
β13 -0.225 -7.09875 -71.7224
β23 -1.875 -5.65875 37.02588
R2 0.9234 0.9060 0.9784
Table 3. Constraints for numeric optimization and predicted solutions
Variable Goal Lower 
limit
Upper limit Importance
Drug (A) In range -1 1 ***
Polymer (B) In range -1 1 ***
Solvent (C) In range -1 1 ***
%EE In range 85.00 94.00 ****
%CDR In range 56.96 88.18 ****
Particle size In range 378.22 923.39 ****
A B C %EE %CDR Particle size Desirability
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0.36 0.82 0.15 88.89 89.07 463.962 1.000 Selected
 Table 4. Various evaluation parameters of matrix tablets
Parameter Value
Average weight (n=20) mg 499.65 ±1.35
Friability test (%) (n=10) 0.69±0.23%
Hardness (n=5) (Kg/cm2) 4.13±0.13
Table 5. Regression cofficient values of  microsponge matrix tablet and microsponge formulation




Zero order kinetic 0.9547 0.9691
First order kinetic 0.8339 0.5933
Higuchi model 0.735 0.8631
Peppas model 0.9894 0.7661
Table 6. Macroscopic evaluation of colonic lesions of rat 
Groups 0 0.5 1 1.5 2
Control _ 1 2 5 1
Resveratrol _ 1 _ 2 _
Microsponge _ 2 1 - _
Matrix Tablet _ 3 2 - _
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